DiaMedica Therapeutics (DMAC)
(Delayed Data from NSDQ)
$4.01 USD
-0.12 (-2.91%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $4.02 +0.01 (0.25%) 7:08 PM ET
2-Buy of 5 2
D Value F Growth B Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
DMAC 4.01 -0.12(-2.91%)
Will DMAC be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for DMAC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DMAC
Is Atossa Genetics (ATOS) Outperforming Other Medical Stocks This Year?
Are Medical Stocks Lagging DiaMedica Therapeutics (DMAC) This Year?
DMAC: What are Zacks experts saying now?
Zacks Private Portfolio Services
DiaMedica (DMAC) Up as Stroke Study Dosing Begins Post Relaunch
DiaMedica Therapeutics (DMAC) Loses -19.8% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Is Cardiol Therapeutics (CRDL) Stock Outpacing Its Medical Peers This Year?
Other News for DMAC
DiaMedica Therapeutics Upcoming Conference Participation
DiaMedica Therapeutics Inc. (DMAC) Q2 2024 Earnings Call Transcript
DiaMedica Therapeutics Provides a Business Update and Announces Second Quarter 2024 Financial Results
DMAC Stock Earnings: DiaMedica Therapeutics Beats EPS for Q2 2024
DiaMedica Therapeutics GAAP EPS of -$0.13 beats by $0.03